Medtronic plc. (MDT) Stock Analysis
Catalyst-Driven edge
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $77.75, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -1.0%/30d (confirmed downtrend).
Medtronic is a global medical device company with four segments—Cardiovascular, Neuroscience, Medical Surgical, and Diabetes—selling device-based therapies and services to healthcare systems in over 150 countries. Revenue is earned from device and consumable sales to hospitals... Read more
Hold if already holding. Not a fresh buy at $77.75, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -1.0%/30d (confirmed downtrend). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: moderate.
Recent Developments — Medtronic plc.
Latest news
- Medtronic plc stock (IE00BTN1Y115): Global leader in medical technology - AD HOC NEWS — AD HOC NEWS positive
- BNY Mellon Dynamic Value Fund's Medtronic PLC(MDT) Holding History - GuruFocus — GuruFocus neutral
- Medtronic shares climb as investors digest legal overhang relief and fresh cardiac-tech updates - Quiver Quantitative — Quiver Quantitative positive
- Medtronic (MDT) stock sinks as market gains: Here's why - MSN — MSN negative
- Thrivent Financial for Lutherans Raises Stock Holdings in Medtronic PLC $MDT - MarketBeat — MarketBeat positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $77.75, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -1.0%/30d (confirmed downtrend). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $97.20 (+25.0%), stop $74.45 (−4.4%), A.R:R 5.0:1. Score 5.5/10, moderate confidence.
Take-profit target: $97.20 (+25.0% upside). Target $97.20 (+25.0%), stop $74.45 (−4.4%), A.R:R 5.0:1. Stop-loss: $74.45.
Weak growth; Below 200-MA, MA slope -1.0%/30d (confirmed downtrend).
Medtronic plc. trades at a P/E of 21.9 (forward 13.0). TrendMatrix value score: 7.1/10. Verdict: Hold.
37 analysts cover MDT with a consensus score of 3.8/5. Average price target: $108.
What does Medtronic plc. do?Medtronic is a global medical device company with four segments—Cardiovascular, Neuroscience, Medical Surgical, and...
Medtronic is a global medical device company with four segments—Cardiovascular, Neuroscience, Medical Surgical, and Diabetes—selling device-based therapies and services to healthcare systems in over 150 countries. Revenue is earned from device and consumable sales to hospitals and physicians; the company has 95,000+ employees and has announced plans to separate its Diabetes business into an independent public company.